Severe community-acquired pneumonia: approach to therapy (Q36765778)

16 August 2017

1 reference

title

Severe community-acquired pneumonia: approach to therapy (English)

1 reference

16 August 2017

Lilibeth Pineda

1

1 reference

16 August 2017

Ali A El Solh

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Pharmacotherapy

16 August 2017

published in

1 reference

16 August 2017

volume

8

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

593-606

1 reference

The burden of community-acquired pneumonia in seniors: results of a population-based study

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Do smoking parents seek the best advice for their asthmatic children?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Defining severe community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

A prediction rule to identify low-risk patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Severe community-acquired pneumonia. Assessment of severity criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Development and validation of a clinical prediction rule for severe community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Etiology and Diagnosis of Pneumonia Requiring ICU Admission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Pneumonia: a deadly disease despite intensive care treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Severe community-acquired pneumonia due to Acinetobacter baumannii.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Methicillin-resistant Staphylococcus aureus disease in three communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: randomised controlled trial. Pakistan Co-trimoxazole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Measuring quality of care with explicit process criteria before and after implementation of the DRG-based prospective payment system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Quality of care, process, and outcomes in elderly patients with pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Early Administration of Antibiotics Does Not Shorten Time to Clinical Stability in Patients With Moderate-to-Severe Community-Acquired Pneumonia *

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Antimicrobial treatment of community acquired pneumonia in adults: A conference report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Improved clinical outcomes with utilization of a community-acquired pneumonia guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Legionnaires disease with bacteremic coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Non-invasive pressure support ventilation in severe community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Intensive insulin therapy in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Intensive insulin therapy in the medical ICU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

A Three-year Study of Severe Community-acquired Pneumonia With Emphasis on Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Drug‐Resistant Pneumococcal Pneumonia: Clinical Relevance and Related Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal Bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

Severe Community-Acquired Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.5.593

21 January 2018

Identifiers

DOI

10.1517/14656566.8.5.593

1 reference

16 August 2017

1 reference